

1 **Interplay between polygenic effects and polypharmacy**
2 **on dementia: An investigation in an elderly Scottish**
3 **cohort.**

4 Vasilis Raptis^{1,2†}, Donncha Mullin^{3,5}, Sumbul Syed⁶, Ian J Deary^{4,7}, Simon R
5 Cox^{4,7}, Tom C Russ^{3,5,7}, Michelle Luciano⁴

6

7 ¹The Roslin Institute, College of Medicine and Veterinary Medicine, University of
8 Edinburgh

9 ²Advanced Care Research Centre, School of Engineering, University of
10 Edinburgh

11 ³Alzheimer Scotland Dementia Research Centre, University of Edinburgh

12 ⁴Department of Psychology, University of Edinburgh

13 ⁵Division of Psychiatry, Centre for Clinical Brain Sciences, University of
14 Edinburgh

15 ⁶School of Health in Social Science, University of Edinburgh

16 ⁷Lothian Birth Cohorts, University of Edinburgh

17

18 † Corresponding author:

19 Vasilis Raptis

20 e-mail: V.Raptis@sms.ed.ac.uk

21

22 **ABSTRACT**

23 INTRODUCTION: Polygenic Risk Scores for Alzheimer dementia (AD-PRS), a
24 measure of aggregate AD genetic risk and polypharmacy have been associated
25 with dementia. Here, we test their interaction's association with future dementia
26 among older adults without baseline neurodegenerative diagnoses.

27 METHODS: Using Cox proportional hazards and mortality-adjusted competing
28 risk regression models we analysed up to 17.5 years all-cause incident dementia
29 in the Lothian Birth Cohort 1936 (n=759, 105 dementia patients). We used
30 polypharmacy (total or nervous-system-acting medications count), AD-PRS, and
31 their interaction as main predictors.

32 RESULTS: A non-significant interaction was found between AD-PRS and total
33 polypharmacy (HR=1.06; p=0.15) or nervous-system-acting polypharmacy
34 (HR=0.98; p=0.86) in shaping dementia risk. Omitting interaction, mortality-
35 adjusted models showed significant AD-PRS prediction of dementia (HR ~1.40;
36 p<0.001), non-significant total (HR=1.03; p=0.49), and nervous-system-acting
37 polypharmacy effects (HR=1.27; p=0.069).

38 DISCUSSION: Elucidating the complex interplay between polypharmacy and
39 genetics could improve management of inappropriate medication in older adults
40 genetically prone to dementia/AD.

41

42 KEYWORDS: Alzheimer dementia, dementia, polygenic risk score,
43 polypharmacy, longitudinal study, gene-environment interaction

44

45 **1 BACKGROUND**

46 Dementia, a condition describing the significant and progressive overall
47 deterioration of a person's cognition with consequent deterioration in function¹, is
48 widely recognised to have multi-factorial causes, arising from the interplay
49 between environmental, lifestyle and genetic factors^{2,3}.

50 Alzheimer dementia (AD), the most frequent cause of dementia (accounting for
51 70 - 80% of dementia⁴) has been extensively shown to have a strong genetic
52 component⁵⁻⁷. Multiple genetic variants have been identified as risk factors for
53 AD through large-scale Genome-Wide Association Studies (GWAS)^{5,6}. The most
54 unequivocally established AD risk gene is apolipoprotein E (*APOE*), located on
55 chromosome 19⁸⁻¹¹. Its coding protein, Apo-E, is an important cholesterol
56 carrying protein, implicated in several brain functions, including lipid transfer,
57 injury repair, neuroinflammation and others. Notably, the *APOE* ϵ 4 allele confers
58 a dramatic increase in AD prevalence (4 to 10 fold increase) and lower age of
59 onset⁸, thus being considered an important genetic risk factor for AD.

60 Other smaller effect AD-associated genes have been implicated in multiple
61 biological processes, including microglia involvement, tau and amyloid- β protein
62 metabolism regulation, immunity, inflammation, cholesterol metabolism, and
63 neurotransmitter regulation^{12,13}. To study the contribution of many genetic loci
64 with small effect, Polygenic Risk Scores (PRS) are often implemented, which
65 estimate a single aggregate score for each individual that is indicative of their
66 genetic liability to a disease¹⁴. For AD, PRS calculated using many AD

67 associated genes have been found in several studies, with varying accuracy, to
68 be predictive of AD risk, even without including the stronger *APOE* genetic
69 effect^{5,6,10,11}. Furthermore, AD-PRS have been associated with cognitive
70 impairment in older healthy adults, as well as several AD related
71 neurodegeneration phenotypes (e.g. neuroimaging changes)¹².

72 Although individuals' genetic variation is fixed at birth, genetic effects are thought
73 to be modified through their interactions with environmental, lifestyle or social
74 factors throughout life. Such gene by environment (GxE) interactions have been
75 suggested in dementia and AD^{3,15}. Specifically for GxE interactions in dementia, it
76 has been proposed that genetic risk for dementia can be mitigated by favourable
77 modifiable lifestyle factors¹⁶⁻¹⁸ (i.e., healthy diet, physical activity, non-smoking,
78 and low alcohol consumption), although with sometimes conflicting results¹⁷. On
79 the other hand, two randomised clinical trials^{19,20} assessing the effect of
80 multidomain lifestyle interventions on dementia found that *APOE* ϵ 4 allele carriers
81 and non-carriers had similar results, indicating no *APOE* ϵ 4 interplay with lifestyle
82 factors. However, most studies so far have focused only on *APOE* genetic
83 variants for GxE interactions^{16,18-20}.

84 Regarding AD-PRS interaction with the environment / lifestyle in shaping
85 dementia or AD risk, less work has been done. In a Chinese cohort study¹⁵,
86 individuals living around higher residential greenness had lower chances of
87 cognitive impairment, with the effect being increased in those having lower PRS
88 genetic risk, although marginally significant. In another study, conducted on a
89 large European cohort, adherence to a healthy lifestyle did not significantly
90 interact with AD PRS in shaping dementia risk².

91 Polypharmacy, a term indicating that someone takes multiple medications, is
92 highly prevalent in older adults with multiple chronic conditions^{21,22}. It has been
93 demonstrated that polypharmacy is associated with unfavourable outcomes, such
94 as increased frequency of falls, increased hospitalisation and hospital
95 readmission, adverse drug reactions and increased mortality^{21,23}. Harmful
96 polypharmacy effects may arise due to drug-drug and drug-disease interactions,
97 especially in older people who have a reduced ability to metabolise drugs²⁴.
98 Specifically for dementia, the role of polypharmacy as a risk factor is less
99 known²⁵. It has been estimated that polypharmacy burden is higher than the
100 general population, given the higher number of comorbid physical conditions in
101 dementia patients^{22,26}, and polypharmacy in people with dementia has been
102 associated with increased emergency hospitalisation and mortality²⁷.

103 Whether the effect of polypharmacy on dementia risk can be modulated by
104 genetic factors is not known. In the present study, it is hypothesised that
105 individuals exposed to polypharmacy have an increased dementia risk if they also
106 have a high genetic risk profile, compared to individuals with a low genetic risk
107 profile. This hypothesis is based on the idea that biological pathways which may
108 be disrupted by drug-disease and drug-drug interactions are also affected by the
109 genetic variants that lead to dementia pathology. For example, anticholinergic
110 drugs, acting on acetylcholine neurotransmitters, have been found to increase
111 dementia risk, adverse outcomes, and are frequent in dementia patients with
112 polypharmacy^{22,28}. At the same time, acetylcholine neurotransmission-related
113 genes (e.g. *RAB10* gene) have been linked with AD pathogenesis¹³. In this study,
114 the proposed hypothesis is addressed in a longitudinal Scottish cohort of older

115 adults, who were relatively healthy and dementia-free at the baseline age of 70
116 years. Specifically, an interaction effect between Alzheimer Disease Polygenic
117 Risk Scores and the number of (1) total and (2) nervous system active baseline
118 drugs is tested in terms of predicting dementia up to 17.5 years of follow-up.

119

120 **2 METHODS**

121 **2.1 Dataset description**

122 The present analysis was conducted on the Lothian Birth Cohort 1936 (LBC1936)
123 dataset²⁹. This is a longitudinal study, designed as a follow-up to the Scottish
124 Mental Survey of 1947 (SMS1947), an intelligence test conducted on pupils aged
125 11 years old across Scotland³⁰. From 2004 to 2007, LBC1936 recruited 1,091
126 participants of the SMS1947, then aged around 70 years old, and mostly living in
127 Lothian at that time²⁹. Since it focussed on 'normal' cognitive ageing initially, no
128 participants had a diagnosis of dementia at baseline. After this first wave of
129 recruitment, participants were re-invited to the study every three years (at mean
130 ages: 73, 76, 79 and 82 years) for follow-up testing, termed Waves 1 to 5
131 respectively. Wave 6 has recently finished, but data is not yet available. At each
132 wave, a wealth of data has been collected from questionnaires, blood tests,
133 physical, medical and cognitive measurements. In addition, participants who have
134 consented to do so, have been linked to their electronic health record to obtain
135 further information about their health status (e.g., disease diagnoses, hospital
136 visits). Detailed descriptions of the LBC1936 have been previously
137 reported^{29,31,32}. For this analysis, information from Wave 1 has been utilised,

138 regarding: participants' demographic characteristics, genetic data and self-
139 reported medication usage and medical conditions. The analysis was conducted
140 on 759 individuals (105 dementia patients, 654 controls) for whom complete
141 genetic data (including *APOE* gene alleles) and ascertained dementia outcome
142 as of August 2022 (see "Outcome: incident dementia" section) were available.

143 **2.2 LBC1936 genetic data**

144 During Wave 1 of the LBC1936, genome-wide genotyping and genotyping of the
145 Apolipoprotein E variants ($\epsilon 2$, $\epsilon 3$, and $\epsilon 4$ alleles) was performed^{29,32} for 1,005
146 individuals. Genotyping of approximately 500,000 genetic variants across the
147 genome (Single Nucleotide Polymorphisms, SNPs) was done using the Illumina
148 Human610-Quadv1 chip³³. Furthermore, non-genotyped variants have been
149 imputed based on the Haplotype Reference Consortium³⁴ reference panel,
150 totalling 39 million SNPs.

151 High quality SNPs and individuals were extracted, in order to minimise
152 genotyping and imputation errors and reduce the chance of biased results³⁵. The
153 quality control filters applied on genotyped data were described in Houlihan et al,
154 2010³³. In brief they included the following: One of each related pair of individuals
155 ($> 2^{\text{nd}}$ degree relatives, i.e., half-siblings) were excluded (n=8); 1 individual with
156 mostly non-European descent was excluded; 12 individuals whose reported and
157 genetically inferred sex did not match (likely indicative of errors during genotype
158 sample preparation) were excluded, and; SNPs that were missing from more than
159 2% of the individuals were excluded. For the present analysis, and on the
160 genotyped and imputed data: 4,360,232 SNPs whose alleles were found in a
161 frequency less than 1% in the cohort were excluded; 55 SNPs that deviated

162 significantly from Hardy-Weinberg Equilibrium were excluded, and; 27.7 million
163 imputed variants with an imputation score less than 0.8 were excluded. These
164 quality control filtering steps were performed using the PLINK(v1.9) software^{36,37}.
165 799 individuals remained after quality control, containing approximately 7 million
166 SNPs. 759 individuals formed the final sample for the analysis, after individuals
167 with missing values in the *APOE* predictor and the covariates were removed (see
168 below).

169 **2.3 Predictors**

170 **2.3.1 Polygenic risk scores**

171 Polygenic Risk Scores (PRS) were used as a risk factor representing the
172 aggregated genome-wide genetic effect contributing to AD. PRS are calculated
173 for each individual as a sum of their genome-wide risk alleles, weighted by each
174 allele's effect size to the outcome (here AD status)¹⁴. For AD-PRS calculation, the
175 allele effect sizes were obtained from the largest to-date European GWAS on AD,
176 totalling up to 85,934 AD patients (Bellenguez et al, 2022)⁵. AD was chosen, as
177 this is the dementia sub-type for which the largest GWAS has been conducted,
178 and the most frequent dementia sub-type in the general population and the
179 present sample (48.6%, Supplementary Table 1).

180 The PRSice2 (v2.3.5) software³⁸ was used to calculate the AD-PRS. PRSice2
181 uses the "clumping and thresholding" technique¹⁴. This means that the total
182 number of SNPs is thinned down to retain only SNPs that are independent from
183 each other (clumping) and significantly associated with the outcome
184 (thresholding). Furthermore, the *APOE* region (chromosome 19, base pair

185 44,000,000 to 46,500,000¹¹, in the human reference genome GRCh37
186 coordinates) was removed before the calculation of the AD-PRS (see “*APOE* ϵ 4
187 alleles” section). Finally, AD-PRS were calculated for the 759 participants with
188 non-missing data, using 981 genome-wide AD associated SNPs at a p-value
189 threshold of < 0.0002 .

190 **2.3.2 *APOE* ϵ 4 alleles**

191 Given the strong effect of the *APOE* ϵ 4 polymorphisms on dementia, it has been
192 suggested for genomic analyses to treat *APOE* polymorphisms independently as
193 a separate predictor^{10,11}, as it can mask the effects of other genetic variants with
194 weaker effects. The *APOE* ϵ 4 polymorphism is thus included as a separate risk
195 factor in the present analysis, defined as the number of ϵ 4 alleles per individual
196 (0, 1 or 2). Since 32 individuals did not have information on *APOE* status, they
197 have been excluded from the analysis, as this is an important risk factor for
198 dementia.

199 **2.3.3 Polypharmacy**

200 Polypharmacy was defined as the count of total or nervous system-acting drugs
201 taken at baseline. Measurements were obtained using LBC1936 participants’
202 medication data. For each wave of the LBC1936, medication data was based on
203 participants’ prescription cards which were brought to the assessment centre and
204 further inspected by the testing team. Data includes prescribed drugs (in their
205 brand name or their generic name), over-the-counter drugs and dietary
206 supplements. To ensure consistency, (e.g., no spelling mistakes, multiple brand
207 names referring to the same drug), we applied several pre-processing steps in

208 order to code each drug name according to the Anatomical Therapeutic
209 Chemical (ATC) classification system³⁹. The ATC classification system classifies
210 the active ingredient(s) of a drug in a 5-level hierarchical code, based on its
211 acting organ/anatomical system and its therapeutic, pharmacological, or chemical
212 properties.

213 Specifically, using only medication data from Wave 1 of LBC1936, the pre-
214 processing steps included:

- 215 • Drugs in their brand names were searched in the British National
216 Formulary (BNF) (<https://bnf.nice.org.uk/>)⁴⁰ and substituted with their
217 generic name.
- 218 • Drugs in their generic name were inspected and corrected for spelling
219 mistakes, also using the BNF website.
- 220 • Subsequently, for each drug's generic name, its corresponding ATC code
221 was retrieved from the ATC classification system's online searchable
222 database (https://www.whocc.no/atc_ddd_index/)³⁹. For drugs with
223 multiple ATC codes (e.g., acting on more than one system), all available
224 ATC codes were retrieved.
- 225 • The following entries were excluded from the analysis:
 - 226 ○ Drugs that could not be assigned to an ATC code
 - 227 ○ homeopathic substances
 - 228 ○ diet supplements
 - 229 ○ vitamins.
- 230 • Additionally, it was deemed appropriate to exclude topically applied
231 dermatological drugs and those with ophthalmic, otic or nasal routes of

232 administration, as they are unlikely to have a systemic effect and interact
233 with pathways affected by AD related genes.

234 After these pre-processing steps were applied, a “general” polypharmacy variable
235 was defined as the total number of drugs taken at Wave 1. Additionally, a
236 nervous-system-specific polypharmacy variable was defined as the number of
237 drugs acting on the central nervous system, based on the corresponding ATC
238 code (code starting with “N0”³⁹).

239 **2.3.4 Other covariates**

240 Apart from the PRS, *APOE* and polypharmacy variables, the following variables
241 were included as covariates: sex, age, BMI, Scottish Index of Multiple Deprivation
242 (SIMD) index, smoking status (non-, ex-, or current smoker), alcohol consumption
243 status (yes or no), number of comorbidities (max 10). The number of
244 comorbidities was calculated by summing the presence, at the time of Wave 1
245 assessment, of self-reported diseases among: high blood pressure, diabetes,
246 high cholesterol, history of cardiovascular disease, stroke, neoplasia, arthritis,
247 Parkinson’s disease, thyroid disease, leg pain or other unspecified disease.
248 Dates of death were identified via data linkage with the National Health Service
249 Central Register, provided by National Records of Scotland. Participant deaths
250 were flagged to the research team approximately every 12 weeks beginning at
251 study baseline. Finally, to account for any residual genomic population
252 stratification⁴¹, which could inflate the effect of the PRS, the 4 first genomic
253 principal components of the individuals were included as covariates.

254 **2.4 Outcome: incident dementia**

255 In a recent endeavour (as described here^{42,43}), dementia outcomes have been
256 ascertained for LBC1936 participants. Briefly, a multi-disciplinary team of clinical
257 dementia experts provided consensus status for dementia and, when possible,
258 dementia sub-types, for all consenting participants⁴². This process included a
259 comprehensive review of participants' electronic health records and death
260 certificates for the presence of dementia. Additionally, when deemed necessary,
261 home visits to suspected dementia patients were conducted by a trained clinician.
262 Finally, a consensus diagnostic review board of experts assessed the strength of
263 evidence for each participant, and categorised each as having "probable",
264 "possible", or "no" dementia, as well as each dementia subtype. The dementia
265 and dementia subtype diagnoses were based on the International Classification
266 of Diseases-11 criteria^{42,44}. Furthermore, the age of onset has been reported as
267 the earliest age for which any diagnosis was reported. Age of onset spanned a
268 time period from approximately one year after attending Wave 1 attendance until
269 mid-August 2022, when the ascertainment process ended⁴².

270 In the present analysis, only "probable" dementia diagnoses were considered,
271 due to the lack of definite evidence for the assignment of a dementia diagnosis in
272 participants with "possible" dementia⁴². The outcome used here was time-to-
273 onset, the time period between Wave 1 assessment until all cause (non-subtype
274 specific) dementia diagnosis in 105 participants.

275 **2.5 Statistical Analysis**

276 The aim of the present study was to determine the effect of AD-PRS, baseline
277 polypharmacy, and their interaction on incident dementia over up to 17.5 years of
278 follow-up. Given the longitudinal nature of the outcome, Cox proportional hazards

279 (Cox PH) models⁴⁵ were implemented. This type of modelling investigates the
280 association between multiple predictors and the time that passes until an
281 outcome event occurs⁴⁶ (here dementia).

282 In a further analysis, to account for the possible bias of individuals dying before
283 exhibiting the main dementia outcome, the Fine-Gray competing risk model^{47,48}
284 was used. This extension of the Cox proportional hazards model estimates the
285 effect of a predictor on the outcome of interest (dementia), given that a competing
286 event has not happened yet (death)⁴⁶. Mirroring the procedure from Mullin et al.
287 (2023)⁴³, for both analyses the time-to-event outcome variables were calculated
288 as the time passing between Wave 1 assessment and the earliest of the
289 following: (1) dementia diagnosis, if the individual was ascertained for dementia,
290 (2) the individual's death, if the participant had died while dementia-free, or (3)
291 end of ascertainment, if the individual was dementia-free and alive at the end of
292 the ascertainment period (mid-August 2022). Statistical models were
293 implemented using the predictors described previously ("Predictors" section), as
294 well as the interaction between AD-PRS and the polypharmacy variables. The
295 results of the models are in the form of Hazard Ratios (HR) with 95% confidence
296 intervals (CI) for each tested predictor.

297 A null model that included only PRS and polypharmacy main effects, without their
298 interaction was also implemented. The statistical analysis for those models was
299 the same as described above.

300 As a sensitivity analysis, cox PH and competing risk models were also run using
301 time to AD diagnosis as outcome (n=51), as described above for the all-cause
302 dementia models.

303 All analyses were conducted using the R (v4.2.2) statistical software⁴⁹, and the
304 packages “survival”⁵⁰ for Cox PH models and “cmprsk”⁴⁸ for competing risk
305 models.

306

307 **3 RESULTS**

308 **3.1 Sample characteristics**

309 After genotyping data cleaning and exclusion of individuals with missing values,
310 the analysis sample consisted of 759 individuals. 105 individuals (13.8%) were
311 diagnosed with dementia up to 17.5 years after follow-up from Wave 1. 51 of
312 these individuals (6.7%) had an Alzheimer dementia diagnosis. Participants’
313 characteristics at Wave 1 for all tested covariates are presented in Table 1.
314 Participants’ mean age at Wave 1 was 69.5 (standard deviation=0.83) years,
315 while the mean age-at-onset for dementia was 80.7 (3.7) years. The median time
316 from baseline to dementia diagnosis for later patients was 11.8 years
317 [interquartile range (IQR): 7.88-14.35]. 277 (49.5%) participants had passed
318 away at the time of censoring,

319 Regarding polypharmacy, 164 (21.6%) of participants took 5 to 10 drugs at the
320 time of Wave 1 testing, while 14 (1.8%) took more than 10 drugs simultaneously
321 (excessive polypharmacy) (Sup. Table 2 and Sup. Figure 3), with a maximum of
322 16 simultaneous drugs. The most abundant drugs by the anatomical system on
323 which they act (according to the ATC classification system³⁹), were those acting
324 on the gastrointestinal system / metabolism (346 individuals taking at least 1,
325 45.6%), cardiovascular system (388 individuals, 5.1%) and nervous system (321

326 individuals, 42.3%) (Sup. Table 2). In addition, individuals taking multiple
327 medications acting on the same system are reported: 141 (18.6%) individuals
328 taking 3 or more cardiovascular medications; 46 (6 %) individuals taking 3 or
329 more gastrointestinal / metabolic medication; and 9 (1.2%) individuals with 3 or
330 more nervous system active medications simultaneously (Table 1 and Sup. Table
331 2).

332

333 Table 1: Descriptive statistics of LBC1936 at Wave 1.

334

Variable	Level	Mean (SD) or n (%)
Sex	Male	392 (51.6)
	Female	368 (48.4)
Age (years)		69.5 (0.83)
BMI (kg/m²)		27.8 (4.24)
SIMD index		4709 (1836)
Smoking status	Never	368 (48.5)
	Ex-Smoker	328 (43.2)
	Current	64 (8.4)
Alcohol status	No	99 (13)
	Yes (current)	661 (87)
Comorbidities index		3.1 (1.8)
APOE ε4 count	0	531 (69.9)
	1	212 (27.9)
	2	17 (2.2)
No. of drugs		2.9 (2.6)
No. NS-active of drugs		0.51 (0.68)
Dementia	No	654 (86.2)
	Yes	105 (13.8)

335
336
337
338
339
340
341
342
343
344
345

Footn
ote:
BMI:
Body
Mass
Index;
SD:
stand
ard

346 deviation; n: number of individuals; SIMD: Scottish Index of Multiple Deprivation;
 347 *APOE*: apolipoprotein E gene; NS-active no. of drugs: number of drugs that act
 348 on the nervous system. Polygenic Risk Scores are not reported as they have
 349 mean 0 and sd 1 by default. *SIMD ranges from 4 (most deprived area) to 6505
 350 (least deprived area).

351


352

353 **3.2 Main analysis**

354 The Cox PH models (unadjusted for death as competing risk) were run using
355 dementia status as the time-to-event outcome variable and polypharmacy
356 (number of drugs), Polygenic Risk Score (PRS) and their interaction
357 (polypharmacy*PRS) as predictors. The models were adjusted for the covariates:
358 *APOE* ϵ 4 count, age, sex, BMI, SIMD index, comorbidities index, alcohol status,
359 smoking status and 4 first genomic principal components. The polypharmacy
360 predictor was either the “general” polypharmacy (total number of drugs) or the
361 nervous system active polypharmacy (number of drugs acting on the nervous
362 system). Cox PH models utilising, among others, age at baseline, sex,
363 comorbidities index and socioeconomic variable as predictors of dementia in
364 LBC1936 have been reported by Mullin et al (2023)⁴³. However, in this previous
365 study motoric cognitive risk instead of polypharmacy / AD-PRS was the main
366 predictor and Wave 3 was the baseline. Both here and in Mullin et al (2023)⁴³
367 these covariates had a non-significant effect on dementia risk.

368 The results for the “general” polypharmacy Cox PH model are presented in the
369 Figure 1 forest plot. Only the *APOE* ϵ 4 allele count significantly increased – more
370 than tripled – the risk of incident dementia over the 17.5-year follow-up (HR =
371 3.28; 95% CI: 2.38 – 4.54; $p = 5.35 \times 10^{-13}$). Taking more drugs and having a high
372 PRS both increased the risk of incident dementia, however, the effects were not
373 significant. For number of drugs: HR = 1.04; 95% CI: 0.93 – 1.15; $p = 0.517$, and
374 for PRS: HR = 1.15; 95% CI: 0.85 - 1.55; $p = 0.376$. The interaction effect
375 between the number of drugs and PRS was in the direction of increased

376 dementia risk above that of their separate effects but was non-significant (HR =
 377 1.06; 95% CI: 0.98 - 1.15; p = 0.135).



378 Figure 1: Forest plot showing the Cox PH model Hazard Ratios for each predictor's association
 379 with all-cause incident dementia. The “no. of drugs” predictor includes all drugs taken by an
 380 individual after data cleaning. HR for Genomic Principal Components are not shown for illustration
 381 purposes, but were included in the model. The forest plot was produced using the “forestmodel” R
 382 package. HR: Hazard Ratio; CI: Confidence Interval; PRS: Polygenic Risk Score; BMI: Body
 383 Mass Index; SIMD: Scottish Index of Multiple Deprivation.


384

385 Figure 2 presents the association results for the Cox PH model that includes the
 386 “nervous system active” polypharmacy predictor. The *APOE* ε4 predictor is,
 387 again, a highly significant risk factor (HR = 3.36; 95% CI: 2.43 – 4.65); p =
 388 2.63x10⁻¹³). This time, however, the number of nervous system active drugs
 389 significantly increased the follow-up dementia risk (HR = 1.37; 95% CI: 1.02 –
 390 1.84; p = 0.035). The positive effect of the PRS was, now, also significant (HR =
 391 1.42; 95% CI: 1.10 – 1.82; p = 0.006). The interaction between the number of

392 nervous system active drugs and the PRS, however, had a non-significant
 393 negative effect (HR = 0.95; 95% CI: 0.72 – 1.25; p = 0.707).

394

395



396 Figure 2: Forest plot showing the Cox PH model Hazard Ratios for each predictor's association
 397 with all-cause incident dementia. The “no. of NS-active drugs” predictor includes drugs acting on
 398 the nervous system taken by an individual. HR for Genomic Principal Components are not shown
 399 for illustration purposes, but were included in the model. The forest plot was produced using the
 400 “forestmodel” R package. HR: Hazard Ratio; CI: Confidence Interval; PRS: Polygenic Risk Score;
 401 BMI: Body Mass Index; SIMD: Scottish Index of Multiple Deprivation; NS-active: nervous system-
 402 active.

403

404 The main results of the Fine – Grey competing risk regression models, adjusting
 405 for mortality as a competing risk of dementia, are presented in Figure 3. Models
 406 were run for both the “general” polypharmacy predictor and the “nervous system-
 407 active” polypharmacy, and their interaction with PRS, adjusting for the full set of

408 covariates. Results for the full list of covariates are presented in Sup. Figure 4.
409 For the “general” polypharmacy model, the results were similar to the unadjusted
410 model, with only the *APOE* ϵ 4 predictor having a significant effect (HR = 3.38;
411 95% CI: 2.46 – 4.66; $p = 8.0 \times 10^{-14}$). “General” polypharmacy, PRS and their
412 interaction all have small, positive, non-significant association with incident
413 dementia, after adjusting for the risk of death (Figure 3, top). Regarding the
414 “nervous system-active” polypharmacy model, the PRS genetic effect remained
415 significant after accounting for death (HR = 1.42; 95% CI: 1.13 – 1.78; $p =$
416 0.0029), but the “nervous system-active” polypharmacy predictor marginally lost
417 significance (HR = 1.27; 95% CI: 0.98 – 1.65; $p = 0.068$). The PRS * “ns-active”
418 polypharmacy interaction was again nonsignificant (HR = 0.98; 95% CI: 0.78 –
419 1.23; $p = 0.86$) (Figure 3, bottom).

420 Because the interaction term was nonsignificant in both models, the mortality
421 adjusted models were re-run omitting this term. Results showed that PRS had a
422 significant positive effect on dementia risk in both general and NS-active
423 polypharmacy models: HR(general) = 1.39; 95% CI: 1.15-1.67; $p < 0.001$ and
424 HR(NS-active) = 1.40; 95% CI: 1.16-1.69; p -value < 0.001 respectively; and that
425 polypharmacy effects were nonsignificant (Sup. Figure 5).


426 Using AD instead of all-cause dementia as outcome did not meaningfully alter the
427 results of either the “general” or the “nervous system-active” polypharmacy
428 models (Sup. Figure 6 and Sup. Figure 7 for AD-specific Cox PH models and
429 Sup. Figure 8 for AD-specific competing risk regression models).

430

431

432

433



434

435 Figure 3: Forest plot showing the Competing Risk Regression models' Hazard Ratios for the
436 association with all-cause incident dementia, adjusting for death as a competing risk. Only
437 predictors of interest are shown here for illustration purposes, but the full set of predictors were
438 included in the models. Upper figure shows the results for the model using the “general”
439 polypharmacy variable (no. of drugs), whereas lower figure shows the results for the nervous-
440 system active no. of drugs. The “Estimates” of the forest plot are Hazard Ratios (HR). CRR:
441 Competing Risk Regression; UCI: Upper Confidence Interval; LCI: Lower Confidence Interval;
442 PRS: Polygenic Risk Score; NS-active: nervous system-active. The forest plot was produced
443 using the “forest” R package.

444

445 4 DISCUSSION

446 4.1 Interpretation of findings

447 This is the first study to assess the interaction between polypharmacy and
448 dementia polygenic risk in shaping all-cause dementia risk. Here, higher
449 polypharmacy exposure, higher polygenic risk (PRS), and their interaction were
450 positively associated with increased dementia risk although only PRS was
451 significant when main effects were considered. The positive direction of effect for
452 the interaction between general polypharmacy and PRS is consistent with our
453 hypothesis that the adverse effects of polypharmacy are modulated by adverse
454 genetic effects which increases the risk of dementia over and above their
455 separate effects. However, the nervous system acting polypharmacy interaction
456 with genetic score had an almost zero non-significant effect. It is possible that the
457 low variability of the predictor (only 9 people with 3 or more nervous system
458 active medications) decreased accurate inferences.

459 Adjusting for death as a competing risk did not substantially change results,
460 indicating that mortality did not affect the association between predictors and
461 dementia. This was unexpected, given the high number of deaths in the sample:
462 277 people in total and 220 people without dementia that could be potential
463 patients otherwise. In these models, and omitting the nonsignificant
464 polypharmacy x PRS interaction effect, the polygenic effect was significant in the
465 hypothesised direction of increased dementia risk. General and NS-active
466 polypharmacy main effects did not alter the risk of dementia, although the latter
467 effect had a larger HR which approached significance indicating potential
468 differences between types of medication used. In previous studies, PRS and
469 polypharmacy have been often associated with dementia risk⁵¹, but they had not
470 been modelled together. Our finding of non-significant polypharmacy effects

471 when controlling for AD polygenic risk might indicate that the previously reported
472 polypharmacy effect on dementia is confounded by polygenic risk for the disease.
473 However, this hypothesis may be difficult to prove using PRS. Here low
474 correlation of AD-PRS with polypharmacy was observed (Pearson's $r=0.041$),
475 and, overall, polygenic scores for complex diseases explain little variation of
476 drug-related phenotypes⁵². *APOE* status is frequently used as a proxy covariate
477 for genetic susceptibility in studies of polypharmacy effects on dementia^{28,53}, with
478 polypharmacy regimes remaining significantly predictive of dementia risk after
479 adjusting for *APOE* status²⁸. One study found that polypharmacy lost significance
480 after adjusting for *APOE* in a population of Aboriginal Australians⁵⁴, although the
481 polypharmacy effect size remained similar with its unadjusted value. Larger
482 longitudinal studies of people with both low and high dementia polygenic risk and
483 low and high polypharmacy use are needed to clarify the role of genetic
484 confounding on polypharmacy effects.

485 The *APOE* gene was the only other covariate that had a significant effect on
486 dementia. This was expected, given its strong and well established role in
487 dementia and AD pathogenesis⁸. Other well established risk factors did not have
488 a significant effect on dementia: BMI, alcohol intake, smoking, and deprivation
489 index, although their effects' direction was expected¹. Inadequate sample size is
490 again a plausible explanation, coupled with restrictions of range in the variables
491 stemming from selection bias in the LBC1936: participants are healthier and from
492 higher socioeconomic status than the general population²⁹.

493 In future, polypharmacy x polygenic interaction effects might be investigated with
494 increased pathway specificity. For example, PRS calculated using only SNPs

495 pertaining to a certain biological pathway (e.g. synaptic processes)¹². Testing
496 whether sub-categories of polypharmacy measurements, such as the nervous
497 system specific polypharmacy predictor, mask the effects of nervous system
498 related pathway-specific PRS could shed light on whether those pathways are
499 modulated by specific drugs. An important caveat, however, is that the predictive
500 ability of pathway-specific PRS are potentially smaller than the genome-wide
501 PRS, so it would be necessary to use large sufficiently powered samples¹².

502 Furthermore, when studying polypharmacy, a direct interpretation of associations
503 with outcomes is difficult as confounding by indication may be present^{28,55}. This
504 means that dementia may be caused not because of polypharmacy, but due to
505 the comorbidities for which multiple drugs are taken. This can affect both the
506 effects of polypharmacy exposure and the polypharmacy interaction with PRS.
507 However, in the present study, the comorbidities index covariate was not
508 significant and had negligible effect, indicating that the presence of comorbid
509 health conditions did not affect dementia risk. This could be again arising due to
510 small sample size, as per previous similar studies in LBC1936⁴³. It could be
511 informative to include separate health conditions that are established dementia
512 risk factors as covariates (e.g., depression, diabetes, and hypertension) and not
513 as part of the comorbidities index covariate. Then, again, small sample size
514 would not allow for the excessive use of covariates, due to the risk of overfitting.

515 **4.2 Strengths and limitations**

516 Several strengths can be identified for the present analysis. First, the high
517 accuracy of the dementia ascertainment outcomes, being based on Electronic
518 Health Records, clinical assessments and expert consensus⁴². This increases the

519 power to detect true associations with dementia risk, compared to non-curated
520 dementia diagnoses. Secondly, the LBC1936 study design provides an
521 appropriate dataset to study dementia, due to the older age of the participants
522 (average of 69.5 years on baseline), extensive follow-up period (up to 17.5 years)
523 and absence of dementia at baseline, allowing for the investigation of risk factors
524 early on during disease development. Thirdly, LBC1936's thorough medication
525 recording protocol, allowing the inclusion of both prescribed and over-the-counter
526 medications in the polypharmacy predictors provides a more accurate picture of
527 the medication state of the individuals. In other studies where polypharmacy is
528 modelled, only prescribed drugs are included^{25,28}, which may underestimate the
529 true polypharmacy burden.

530 On the other hand, several limitations should be acknowledged. The major
531 limitation of the study is the low sample size. Detecting genotype by environment
532 interactions requires very large sample sizes, given their postulated small effect
533 sizes³. Additionally, the definition of polypharmacy as the number of (systemic or
534 nervous system acting) drugs taken at a certain time point (Wave 1 testing) is not
535 optimal, as it lacks information on the duration of exposure and adherence to the
536 medication. A better metric would be the number of daily drugs taken²¹ and the
537 time period, however no such information was available. Electronic Health
538 Records data may allow for such modelling. Finally, only baseline (Wave 1)
539 information for all predictors was used (polypharmacy, covariates). Cumulatively
540 incorporating the changes in the predictors over time until dementia diagnosis
541 would improve the power to detect true associations. That is, using information
542 from later waves to construct time-varying predictor variables in the Cox PH

543 models is a sensible future direction for better delineating polypharmacy
544 trajectories.

545

546 **5 CONCLUSIONS**

547 In summary, in the present analysis it was hypothesised that the detrimental
548 effect of polypharmacy on dementia is modulated by one's genetic profile, with
549 high genetic risk exacerbating adverse polypharmacy effects. This interaction
550 effect was not supported for general polypharmacy or nervous system acting
551 polypharmacy. AD polygenic scores were associated with increased risk of
552 dementia, and there was suggestion that nervous system active drugs had
553 independent polypharmacy effects on dementia risk. Better characterising how
554 polypharmacy exerts adverse effects on individuals with high or low dementia
555 genetic risk may point towards supporting the case for de-prescribing
556 inappropriate medications in older adults dependent on one's genetic risk
557 towards dementia.

558

559 **ACKNOWLEDGEMENTS**

560 We are thankful to Dr. Sarah Harris and Dr. Jure Mur for the insightful
561 discussions on various topics of the project and LBC1936, and to Paul Redmond
562 and Dr. Gail Davies for guidance and assistance on data access.

563 This research was funded by the Legal & General Group (research grant to
564 establish the independent Advanced Care Research Centre at University of

565 Edinburgh). The funder had no role in conduct of the study, interpretation or the
566 decision to submit for publication. The views expressed are those of the authors
567 and not necessarily those of Legal & General. The LBC1936 study is supported
568 by the Biotechnology and Biological Sciences Research Council (BBSRC) and
569 the ESRC (BB/W008793/1), Age UK (Disconnected Mind project), the Milton
570 Damerel Trust, and the University of Edinburgh. SRC was supported by a Sir
571 Henry Dale Fellowship jointly funded by the Wellcome Trust and the Royal
572 Society (221890/Z/20/Z). The Lothian Birth Cohort 1936 study acknowledges the
573 financial support of NHS Research Scotland (NRS), through Edinburgh Clinical
574 Research Facility. We gratefully acknowledge the contributions of the LBC1936
575 participants and members of the LBC1936 research team who collect and
576 manage the LBC data.

577 All authors declare no competing interests.

578

579 REFERENCES

580

- 581 1. Livingston G, Huntley J, Liu KY, et al. Dementia prevention, intervention, and care: 2024
582 report of the Lancet standing Commission. *The Lancet*. 2024;404(10452):572-628.
583 doi:10.1016/S0140-6736(24)01296-0
- 584 2. Lourida I, Hannon E, Littlejohns TJ, et al. Association of Lifestyle and Genetic Risk With
585 Incidence of Dementia. *JAMA*. 2019;322(5):430. doi:10.1001/jama.2019.9879
- 586 3. Dunn AR, O'Connell KMS, Kaczorowski CC. Gene-by-environment interactions in Alzheimer's
587 disease and Parkinson's disease. *Neuroscience & Biobehavioral Reviews*. 2019;103:73-80.
588 doi:10.1016/j.neubiorev.2019.06.018
- 589 4. Reitz C, Mayeux R. Alzheimer disease: Epidemiology, diagnostic criteria, risk factors and
590 biomarkers. *Biochemical Pharmacology*. 2014;88(4):640-651. doi:10.1016/j.bcp.2013.12.024
- 591 5. Bellenguez C. New insights into the genetic etiology of Alzheimer's disease and related
592 dementias. *Nature Genetics*. 2022;54.

- 593 6. Alzheimer Disease Genetics Consortium (ADGC), The European Alzheimer's Disease Initiative
594 (EADI), Cohorts for Heart and Aging Research in Genomic Epidemiology Consortium
595 (CHARGE), et al. Genetic meta-analysis of diagnosed Alzheimer's disease identifies new risk
596 loci and implicates A β , tau, immunity and lipid processing. *Nat Genet.* 2019;51(3):414-430.
597 doi:10.1038/s41588-019-0358-2
- 598 7. Gatz M, Reynolds CA, Fratiglioni L, et al. Role of Genes and Environments for Explaining
599 Alzheimer Disease. *Arch Gen Psychiatry.* 2006;63(2):168. doi:10.1001/archpsyc.63.2.168
- 600 8. Liu CC, Kanekiyo T, Xu H, Bu G. Apolipoprotein E and Alzheimer disease: risk, mechanisms
601 and therapy. *Nat Rev Neurol.* 2013;9(2):106-118. doi:10.1038/nrneurol.2012.263
- 602 9. Gharbi-Meliani A, Dugravot A, Sabia S, et al. The association of APOE ϵ 4 with cognitive
603 function over the adult life course and incidence of dementia: 20 years follow-up of the
604 Whitehall II study. *Alz Res Therapy.* 2021;13(1):5. doi:10.1186/s13195-020-00740-0
- 605 10. Ware EB, Faul JD, Mitchell CM, Bakulski KM. Considering the APOE locus in Alzheimer's
606 disease polygenic scores in the Health and Retirement Study: a longitudinal panel study.
607 *BMC Med Genomics.* 2020;13(1):164. doi:10.1186/s12920-020-00815-9
- 608 11. Leonenko G, Baker E, Stevenson-Hoare J, et al. Identifying individuals with high risk of
609 Alzheimer's disease using polygenic risk scores. *Nat Commun.* 2021;12(1):4506.
610 doi:10.1038/s41467-021-24082-z
- 611 12. Harrison JR, Mistry S, Muskett N, Escott-Price V. From Polygenic Scores to Precision
612 Medicine in Alzheimer's Disease: A Systematic Review. Brookes K, ed. *JAD.* 2020;74(4):1271-
613 1283. doi:10.3233/JAD-191233
- 614 13. Seto M, Weiner RL, Dumitrescu L, Hohman TJ. Protective genes and pathways in Alzheimer's
615 disease: moving towards precision interventions. *Mol Neurodegeneration.* 2021;16(1):29.
616 doi:10.1186/s13024-021-00452-5
- 617 14. Choi SW, Mak TSH, O'Reilly PF. Tutorial: a guide to performing polygenic risk score analyses.
618 *Nat Protoc.* 2020;15(9):2759-2772. doi:10.1038/s41596-020-0353-1
- 619 15. Jin X, Shu C, Zeng Y, Liang L, Ji JS. Interaction of greenness and polygenic risk score of
620 Alzheimer's disease on risk of cognitive impairment. *Science of The Total Environment.*
621 2021;796:148767. doi:10.1016/j.scitotenv.2021.148767
- 622 16. Huang TL, Zandi PP, Tucker KL, et al. Benefits of fatty fish on dementia risk are stronger for
623 those without APOE ϵ 4. *Neurology.* 2005;65(9):1409-1414.
624 doi:10.1212/01.wnl.0000183148.34197.2e
- 625 17. Licher S, Ahmad S, Karamujić-Čomić H, et al. Genetic predisposition, modifiable-risk-factor
626 profile and long-term dementia risk in the general population. *Nat Med.* 2019;25(9):1364-
627 1369. doi:10.1038/s41591-019-0547-7
- 628 18. Kivipelto M, Rovio S, Ngandu T, et al. Apolipoprotein E ϵ 4 magnifies lifestyle risks for
629 dementia: a population-based study. *Journal of Cellular and Molecular Medicine.*
630 2008;12(6b):2762-2771. doi:10.1111/j.1582-4934.2008.00296.x

- 631 19. Solomon A, Turunen H, Ngandu T, et al. Effect of the Apolipoprotein E Genotype on
632 Cognitive Change During a Multidomain Lifestyle Intervention: A Subgroup Analysis of a
633 Randomized Clinical Trial. *JAMA Neurol.* 2018;75(4):462. doi:10.1001/jamaneurol.2017.4365
- 634 20. Rovio S, K reholt I, Helkala EL, et al. Leisure-time physical activity at midlife and the risk of
635 dementia and Alzheimer’s disease. *The Lancet Neurology.* 2005;4(11):705-711.
636 doi:10.1016/S1474-4422(05)70198-8
- 637 21. Masnoon N, Shakib S, Kalisch-Ellett L, Caughey GE. What is polypharmacy? A systematic
638 review of definitions. *BMC Geriatr.* 2017;17(1):230. doi:10.1186/s12877-017-0621-2
- 639 22. Esumi S, Ushio S, Zamami Y. Polypharmacy in Older Adults with Alzheimer’s Disease.
640 *Medicina.* 2022;58(10):1445. doi:10.3390/medicina58101445
- 641 23. Fried TR, O’Leary J, Towle V, Goldstein MK, Trentalange M, Martin DK. Health Outcomes
642 Associated with Polypharmacy in Community-Dwelling Older Adults: A Systematic Review. *J*
643 *Am Geriatr Soc.* 2014;62(12):2261-2272. doi:10.1111/jgs.13153
- 644 24. Bushardt R. Polypharmacy: Misleading, but manageable. *CIA.* 2008;Volume 3:383-389.
645 doi:10.2147/CIA.S2468
- 646 25. Park HY, Park JW, Song HJ, Sohn HS, Kwon JW. The Association between Polypharmacy and
647 Dementia: A Nested Case-Control Study Based on a 12-Year Longitudinal Cohort Database in
648 South Korea. Laks J, ed. *PLoS ONE.* 2017;12(1):e0169463. doi:10.1371/journal.pone.0169463
- 649 26. Clague F, Mercer SW, McLean G, Reynish E, Guthrie B. Comorbidity and polypharmacy in
650 people with dementia: insights from a large, population-based cross-sectional analysis of
651 primary care data. *Age Ageing.* Published online October 13, 2016:ageing;afw176v1.
652 doi:10.1093/ageing/afw176
- 653 27. Mueller C, Molokhia M, Perera G, et al. Polypharmacy in people with dementia: Associations
654 with adverse health outcomes. *Experimental Gerontology.* 2018;106:240-245.
655 doi:10.1016/j.exger.2018.02.011
- 656 28. Mur J, Russ TC, Cox SR, Marioni RE, Muniz-Terrera G. Association between anticholinergic
657 burden and dementia in UK Biobank. *A&D Transl Res & Clin Interv.* 2022;8(1):e12290.
658 doi:10.1002/trc2.12290
- 659 29. Taylor AM, Pattie A, Deary IJ. Cohort Profile Update: The Lothian Birth Cohorts of 1921 and
660 1936. *International Journal of Epidemiology.* 2018;47(4):1042-1042r. doi:10.1093/ije/dyy022
- 661 30. *The Trend of Scottish Intelligence: A Comparison of the 1947 and 1932 Surveys of the*
662 *Intelligence of Eleven-Year-Old Pupils.* University London Press; 1949:xxviii, 151.
- 663 31. Deary IJ, Whalley LJ, Starr JM. A lifetime of intelligence: Follow-up studies of the Scottish
664 mental surveys of 1932 and 1947. *A lifetime of intelligence: Follow-up studies of the Scottish*
665 *mental surveys of 1932 and 1947.* Published online 2009:xvi, 285-xvi, 285.
666 doi:10.1037/11857-000
- 667 32. Deary IJ, Gow AJ, Pattie A, Starr JM. Cohort Profile: The Lothian Birth Cohorts of 1921 and
668 1936. *International Journal of Epidemiology.* 2012;41(6):1576-1584. doi:10.1093/ije/dyr197

- 669 33. Houlihan LM, Davies G, Tenesa A, et al. Common Variants of Large Effect in F12, KNG1, and
670 HRG Are Associated with Activated Partial Thromboplastin Time. *The American Journal of*
671 *Human Genetics*. 2010;86(4):626-631. doi:10.1016/j.ajhg.2010.02.016
- 672 34. the Haplotype Reference Consortium. A reference panel of 64,976 haplotypes for genotype
673 imputation. *Nat Genet*. 2016;48(10):1279-1283. doi:10.1038/ng.3643
- 674 35. Weale ME. Quality Control for Genome-Wide Association Studies. In: Barnes MR, Breen G,
675 eds. *Genetic Variation*. Vol 628. Methods in Molecular Biology. Humana Press; 2010:341-
676 372. doi:10.1007/978-1-60327-367-1_19
- 677 36. Chang CC, Chow CC, Tellier LC, Vattikuti S, Purcell SM, Lee JJ. Second-generation PLINK:
678 rising to the challenge of larger and richer datasets. *GigaSci*. 2015;4(1):7.
679 doi:10.1186/s13742-015-0047-8
- 680 37. Purcell SM, Chang CC. PLINK v1.9. www.cog-genomics.org/plink/1.9/
- 681 38. Choi SW, O'Reilly PF. PRSice-2: Polygenic Risk Score software for biobank-scale data.
682 *GigaScience*. 2019;8(7):giz082. doi:10.1093/gigascience/giz082
- 683 39. ATC/DDD Index 2023. WHO Collaborating Centre for Drug Statistics Methodology. Accessed
684 January 7, 2023. https://www.whocc.no/atc_ddd_index/
- 685 40. British National Formulary (BNF). National Institute for Health and Care Excellence (NICE).
686 Accessed January 7, 2023. <https://bnf.nice.org.uk/>
- 687 41. Uffelmann E, Huang QQ, Munung NS, et al. Genome-wide association studies. *Nat Rev*
688 *Methods Primers*. 2021;1(1):59. doi:10.1038/s43586-021-00056-9
- 689 42. Mullin DS, Stirland LE, Buchanan E, et al. Identifying dementia using medical data linkage in a
690 longitudinal cohort study: Lothian Birth Cohort 1936. *BMC Psychiatry*. 2023;23(1):303.
691 doi:10.1186/s12888-023-04797-7
- 692 43. Mullin DS, Gadd D, Russ TC, Luciano M, Muniz-Terrera G. Motoric cognitive risk syndrome
693 trajectories and incident dementia over 10 years. *Cerebral Circulation - Cognition and*
694 *Behavior*. 2023;5:100178. doi:10.1016/j.cccb.2023.100178
- 695 44. International Classification of Diseases, Eleventh Revision (ICD-11), World Health
696 Organization (WHO) 2019/2021. <https://icd.who.int/en>
- 697 45. Cox DR. Regression Models and Life-Tables. *Journal of the Royal Statistical Society Series B*
698 *(Methodological)*. 1972;34(2):187-220.
- 699 46. Kalbfleisch JD, Schaubel DE. Fifty Years of the Cox Model. *Annu Rev Stat Appl*. 2023;10(1):1-
700 23. doi:10.1146/annurev-statistics-033021-014043
- 701 47. Austin PC, Fine JP. Practical recommendations for reporting Fine-Gray model analyses for
702 competing risk data. *Statistics in Medicine*. 2017;36(27):4391-4400. doi:10.1002/sim.7501
- 703 48. Fine JP, Gray RJ. A Proportional Hazards Model for the Subdistribution of a Competing Risk.
704 *Journal of the American Statistical Association*. 1999;94(446):496-509.
705 doi:10.1080/01621459.1999.10474144

- 706 49. R Core Team. R: A language and environment for statistical computing. Published online
707 2022. <https://www.R-project.org/>
- 708 50. Therneau T. A Package for Survival Analysis in R. [https://CRAN.R-](https://CRAN.R-project.org/package=survival)
709 [project.org/package=survival](https://CRAN.R-project.org/package=survival)
- 710 51. Leelakanok N, D’Cunha RR. Association between polypharmacy and dementia – A systematic
711 review and metaanalysis. *Aging & Mental Health*. 2019;23(8):932-941.
712 doi:10.1080/13607863.2018.1468411
- 713 52. Simona A, Song W, Bates DW, Samer CF. Polygenic risk scores in pharmacogenomics:
714 opportunities and challenges—a mini review. *Front Genet*. 2023;14:1217049.
715 doi:10.3389/fgene.2023.1217049
- 716 53. Gray SL, Anderson ML, Dublin S, et al. Cumulative Use of Strong Anticholinergics and
717 Incident Dementia: A Prospective Cohort Study. *JAMA Intern Med*. 2015;175(3):401.
718 doi:10.1001/jamainternmed.2014.7663
- 719 54. Lavrencic LM, Delbaere K, Broe GA, et al. Dementia Incidence, *APOE* Genotype, and Risk
720 Factors for Cognitive Decline in Aboriginal Australians: A Longitudinal Cohort Study.
721 *Neurology*. 2022;98(11). doi:10.1212/WNL.00000000000013295
- 722 55. Kyriacou DN, Lewis RJ. Confounding by Indication in Clinical Research. *JAMA*.
723 2016;316(17):1818. doi:10.1001/jama.2016.16435
- 724